ClinicalTrials.gg
Not yet recruitingNCT05990127Updated Aug 14, 2023

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

A Phase 3 interventional study of AK104 and Tislelizumab in Locally Advanced or Metastatic NSCLC, sponsored by Akeso. Not yet recruiting at 62 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
642
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung — 10 open to participants now, 13 under way, 2 of them phase 3. cadonilimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
Largest of 15
642 · median 44
Started
2023
with 7 others
Phase 3
2 of 15
2 open now
Primary completion
2025-08
later than 5 of 12 live
Registered
7th of 15
by date
Lead sponsor
4 of 15
Akeso

Among the 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung, this one has the largest planned enrollment, is one of 8 that started in 2023, is one of 2 in phase 3, reaches primary completion later than 5 of the 12 other live ones, and was the 7th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

10 of the 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About cadonilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK104 combined chemotherapy versus Tislelizumab combined chemotherapy in first-line treatment of Locally advanced or metastatic NSCLC with PD-L1 TPS \< 1%.

03

Conditions studied

  • Locally Advanced or Metastatic NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subjects voluntarily participated in the study with full and signed written informed consent form.
  2. Aged ≥18 years when the subject signed the informed consent.
  3. (ECOG) performance status of 0 or 1.
  4. ≥ 3 months.
  5. or cytologically confirmed locally advanced (Stage IIIB/IIIC) that not amenable to complete surgical resection and not amenable to radical concurrent/sequential chemoradiation or (Stage IV) NSCLC (American Joint Committee on Cancer [AJCC] 8th edition).
  6. No prior systemic therapy for advanced or metastatic NSCLC was received.
  7. TPS \< 1%.
  8. No EGFR sensitive mutations or ALK gene translocation alterations.

Exclusion criteria

Exclusion Criteria:

  1. confirmed small cell lung cancer (SCLC).
  2. NSCLC with driver gene mutations for approved targeted drug indications.
  3. Active central nervous system (CNS) were present.
  4. Pulmonary radiation therapy > 30 Gy within 6 months prior to first dose.
  5. Active malignant tumors within the past 5 years, except for tumors in this study and scured local tumors.
  6. Pregnant or lactating women.
  7. cardiovascular or cerebrovascular disease.
  8. Subjects with a known history of severe to other monoclonal antibodies. A known history of allergy or hypersensitivity to all drugs or any of their components.
  9. Active disease requiring systemic treatment within 2 years prior to the start of study treatment, or autoimmune diseases that may relapse or require scheduled treatment as judged by the Investigator.
  10. Known active pulmonary tuberculosis.
  11. Patients with active or active .
  12. Known medical history of immunodeficiency or positive test.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
642 participants (estimated)

Study arms

  • Experimental
    AK104 arm

    Drug: AK104 · Drug: carboplatin · Drug: Pemetrexed · Drug: Paclitaxel

  • Active comparator
    Tislelizumab arm

    Drug: Tislelizumab · Drug: carboplatin · Drug: Pemetrexed · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival(OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

  2. Progression-Free Survival(PFS) by investigator(INV)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

Secondary outcomes

  1. Progression-Free Survival(PFS) by Blind independent center review(BIRC)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

  2. Objective response rate (ORR) was assessed by INV

    ORR is the proportion of subjects with CR or PR based on RECIST v1.1

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

  3. Disease control rate (DCR) was assessed by INV

    Disease control rate (DCR) was assessed based on RECIST V1.1 criteria

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

  4. Time to response (TTR) was assessed by INV

    The time from the first administration to the date of documented CR or PR

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

  5. Duration of response (DOR) was assessed by INV

    Measured from the date of partial or complete response to therapy until the disease progression per RECIST v1.1 criteria

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

  6. Objective response rate (ORR) was assessed by BIRC

    ORR is the proportion of subjects with CR or PR based on RECIST v1.1

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

  7. Disease control rate (DCR) was assessed BIRC

    Disease control rate (DCR) was assessed based on RECIST V1.1 criteria

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

  8. Time to response (TTR) was assessed by BIRC

    The time from the first administration to the date of documented CR or PR

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

  9. Duration of response (DOR) was assessed by BIRC

    Measured from the date of partial or complete response to therapy until the disease progression per RECIST v1.1 criteria

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

  10. The number of subjects experiencing adverse events (AEs)

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), and clinically significant abnormal laboratory results.

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

  11. Pharmacokinetic

    The endpoints for assessment of PK of AK104 include serum concentrations of AK104 at different timepoints after AK104 administration

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

  12. Antidrug antibodies (ADA) of AK104

    Proportion of subjects who develop detectable anti-drug antibodies (ADAs)

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

  13. Health-related Quality of Life (HRQoL) assessment using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    EORTC QLQ-C30 measures cancer patients' physical, psychological, and social functions. Scale ranges from: 1, "Not at all"; 2, "A little"; 3, "Quite a bit"; to 4, "Very much". Higher score for the functioning scales and global health status denotes a better level of functioning, while higher scores on the symptom and single-item scales indicate a higher level of symptoms.

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

  14. Health-related Quality of Life (HRQoL) assessment using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 29 module (EORTC QLQ-LC29)

    EORTC-QLQ-LC29 measures the quality of life in patients with lung cancer. Symptom scale ranges from: 1, "Not at all"; 2, "A little"; 3, "Quite a bit"; to 4, "Very much". For symptoms scales, higher scores indicated greater symptom burden.

    Time frame: Through Database Cutoff Date (Up to approximately 39 months)

07

Study locations

62 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2023; primary completion for Aug 2025, 20 months later.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 20 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2023
First posted
Aug 14, 2023
StartEst.
Nov 14, 2023
Primary completionEst.
Aug 5, 2025
CompletionEst.
Nov 28, 2026
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05990127
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Nov 14, 2023 (estimated)
Primary completion
Aug 5, 2025 (estimated)
Completion
Nov 28, 2026 (estimated)
Last update
Aug 14, 2023

Study contacts

Zhifang Yao, M.D.
Contact
clinicaltrials@akesobio.com
+86-0760-89873999
Jie Wang, M.D.
principal investigator · Cancer hospital, Chinese academy of medical sciences and Peking union medical college
Qingming Wang
principal investigator · Henan Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cadonilimab

Start the discussion